Abstract
Multilamellar liposomal amphotericin B (L-AmB) was generally less active in vitro against yeast strains than was amphotericin B-deoxycholate or free amphotericin B, although continual agitation of the broth disproportionately increased the activity of L-AmB. Time-kill studies also demonstrated a slower onset of action of L-AmB and supported the hypothesis that liposomes may act as reservoirs for free amphotericin B, which is the active moiety.
Full text
PDF



Images in this article
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Brajtburg J., Powderly W. G., Kobayashi G. S., Medoff G. Amphotericin B: delivery systems. Antimicrob Agents Chemother. 1990 Mar;34(3):381–384. doi: 10.1128/aac.34.3.381. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hopfer R. L., Mills K., Mehta R., Lopez-Berestein G., Fainstein V., Juliano R. L. In vitro antifungal activities of amphotericin B and liposome-encapsulated amphotericin B. Antimicrob Agents Chemother. 1984 Mar;25(3):387–389. doi: 10.1128/aac.25.3.387. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Juliano R. L., Grant C. W., Barber K. R., Kalp M. A. Mechanism of the selective toxicity of amphotericin B incorporated into liposomes. Mol Pharmacol. 1987 Jan;31(1):1–11. [PubMed] [Google Scholar]
- Jullien S., Brajtburg J., Bolard J. Affinity of amphotericin B for phosphatidylcholine vesicles as a determinant of the in vitro cellular toxicity of liposomal preparations. Biochim Biophys Acta. 1990 Jan 15;1021(1):39–45. doi: 10.1016/0005-2736(90)90381-w. [DOI] [PubMed] [Google Scholar]
- Jullien S., Contrepois A., Sligh J. E., Domart Y., Yeni P., Brajtburg J., Medoff G., Bolard J. Study of the effects of liposomal amphotericin B on Candida albicans, Cryptococcus neoformans, and erythrocytes by using small unilamellar vesicles prepared from saturated phospholipids. Antimicrob Agents Chemother. 1989 Mar;33(3):345–349. doi: 10.1128/aac.33.3.345. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Lopez-Berestein G., Bodey G. P., Frankel L. S., Mehta K. Treatment of hepatosplenic candidiasis with liposomal-amphotericin B. J Clin Oncol. 1987 Feb;5(2):310–317. doi: 10.1200/JCO.1987.5.2.310. [DOI] [PubMed] [Google Scholar]
- Lopez-Berestein G., Fainstein V., Hopfer R., Mehta K., Sullivan M. P., Keating M., Rosenblum M. G., Mehta R., Luna M., Hersh E. M. Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: a preliminary study. J Infect Dis. 1985 Apr;151(4):704–710. doi: 10.1093/infdis/151.4.704. [DOI] [PubMed] [Google Scholar]
- Lopez-Berestein G., Mehta R., Hopfer R. L., Mills K., Kasi L., Mehta K., Fainstein V., Luna M., Hersh E. M., Juliano R. Treatment and prophylaxis of disseminated infection due to Candida albicans in mice with liposome-encapsulated amphotericin B. J Infect Dis. 1983 May;147(5):939–945. doi: 10.1093/infdis/147.5.939. [DOI] [PubMed] [Google Scholar]
- Mehta R., Lopez-Berestein G., Hopfer R., Mills K., Juliano R. L. Liposomal amphotericin B is toxic to fungal cells but not to mammalian cells. Biochim Biophys Acta. 1984 Mar 14;770(2):230–234. doi: 10.1016/0005-2736(84)90135-4. [DOI] [PubMed] [Google Scholar]
- Szoka F. C., Jr, Milholland D., Barza M. Effect of lipid composition and liposome size on toxicity and in vitro fungicidal activity of liposome-intercalated amphotericin B. Antimicrob Agents Chemother. 1987 Mar;31(3):421–429. doi: 10.1128/aac.31.3.421. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Weber R. S., Lopez-Berestein G. Treatment of invasive Aspergillus sinusitis with liposomal-amphotericin B. Laryngoscope. 1987 Aug;97(8 Pt 1):937–941. [PubMed] [Google Scholar]